Portola Pharmaceuticals Announces Betrixaban and AndexXa™ (andexanet alfa) Presentations at ACC.17
08 March 2017 - 8:05AM
Portola Pharmaceuticals Inc.® (Nasdaq:PTLA) today announced
that new data from the pivotal Phase 3 APEX Study of the
Company’s investigational drug betrixaban will be presented in a
poster session at the upcoming American College of Cardiology’s
(ACC) 66th Annual Scientific Session & Expo, which is taking
place from March 17-19 at the Walter E. Washington Convention
Center in Washington, D.C. Additionally, clinical data on
betrixaban and on the Company’s investigational agent AndexXa™
(andexanet alfa) will be discussed during an oral session titled,
“Challenging the Standard of Care: Emerging Concepts in VTE
Treatment and Prevention.”
Betrixaban, which has Fast Track designation from the U.S. Food
and Drug Administration (FDA), is an oral, once-daily Factor Xa
inhibitor anticoagulant in development for the extended prophylaxis
of venous thromboembolism (VTE) in acute medically ill patients
with risk factors for VTE. AndexXa, a U.S. Food and Drug
Administration (FDA)-designated Breakthrough Therapy, is in
development for patients treated with a direct (apixaban,
rivaroxaban or edoxaban) or indirect (enoxaparin) Factor Xa
inhibitor when reversal of anticoagulation is needed due to
life-threatening or uncontrolled bleeding.
The betrixaban poster will include additional data that is not
available in the abstract, which is currently available on the ACC
website.
Betrixaban
- Abstract Title: Extended Duration Betrixaban
Reduces the Risk of Venous Thromboembolism Versus Standard Duration
Enoxaparin in the Post Parenteral Period Among Hospitalized
Medically Ill PatientsPoster #:
055Presenting Author: Serge Korjian, M.D., Beth
Israel Deaconess Medical Center, Boston Session
Title: Diabetes and Other Issues in Cardiovascular
Prevention Presentation Date and Time:
Sunday, March 19, 9:45-10:30 a.m. ETPresentation
Location: Poster Hall, Hall C
- Presentation Title: Extended Pharmacological
Thromboprophylaxis at Hospital Discharge for High Risk Medical
PatientsPresenting Author: Alexander (Ander) T.
Cohen, MBBS, M.Sc., M.D., FRACP, APEX Co-Principal Investigator and
Co-Chairman of the APEX Executive Committee and consultant
physician at Guy’s and St Thomas’ NHS Foundation
TrustSession Title: Challenging the Standard of
Care: Emerging Concepts in VTE Treatment and
PreventionSession Number: 637Presentation
Date and Time: Friday, March 17, 2:48-3:00 p.m.
ETPresentation Location: Room 209 C
AndexXa™ (andexanet alfa)
- Presentation Title: Managing Life-threatening
Bleeding in Patients Taking Non-Vitamin K Oral Anticoagulants: When
and How to Use Reversal AgentsPresenting Author:
Samuel Goldhaber, M.D., senior physician, Brigham and Women’s
Hospital, Boston Session Title: Challenging
the Standard of Care: Emerging Concepts in VTE Treatment and
PreventionSession Number: 637Presentation
Date and Time: Friday, March 17, 2:24-2:36 p.m.
ETPresentation Location: Room 209 C
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a biopharmaceutical company
developing product candidates that could significantly advance the
fields of thrombosis and other hematologic diseases. The Company is
advancing three programs, including betrixaban, an oral, once-daily
Factor Xa inhibitor; AndexXa™ (andexanet alfa), a recombinant
protein designed to reverse the anticoagulant effect in patients
treated with an oral or injectable Factor Xa inhibitor; and
cerdulatinib, a Syk/JAK inhibitor in development to treat
hematologic cancers. Portola's partnered program is focused on
developing selective Syk inhibitors for inflammatory conditions.
For more information, visit http://www.portola.com and follow
the Company on Twitter @Portola_Pharma.
Investor Contact:
Ana Kapor
Portola Pharmaceuticals
ir@portola.com
Media Contact:
Julie Normart
Pure Communications
jnormart@purecommunications.com
415.946.1087
Portola Pharmaceuticals (NASDAQ:PTLA)
Historical Stock Chart
From Apr 2024 to May 2024
Portola Pharmaceuticals (NASDAQ:PTLA)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Portola Pharmaceuticals Inc (NASDAQ): 0 recent articles
More News Articles